Soligenix

Soligenix Net Change in Cash

The Net Change in Cash of Soligenix (SNGX) as of Oct 17, 2026 is 116,639.00 USD. In the previous year, Net Change in Cash was -626,644.00 USD — a change of -118.61% (higher).

Net Change in Cash

116,639.00USD

YoY

-118.61%

Last updated:

Net Change in Cash of Soligenix is 2025 116,639.00 USD. Net Change in Cash of Soligenix was 2024 -626,644.00 USD. It decreases by -118.61% higher compared to the previous year.

The Soligenix Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
1.17 M USD
Jan 1, 2019
-3.56 M USD
Jan 1, 2020
13.26 M USD
Jan 1, 2021
7.37 M USD
Jan 1, 2022
-12.68 M USD
Jan 1, 2023
-4.91 M USD
Jan 1, 2024
-626,644.00 USD
Jan 1, 2025
116,639.00 USD
The Soligenix Net Change in Cash history
YEARNet Change in CashYoY
116,639.00USD-118.61%
-626,644.00USD-87.25%
-4.91 MUSD-61.26%
-12.68 MUSD-272.17%
7.37 MUSD-44.42%
13.26 MUSD-472.04%
-3.56 MUSD-403.43%
1.17 MUSD-221.92%
-963,080.00USD-125.01%
3.85 MUSD-738.06%
-603,549.00USD+82.26%
-331,148.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Net Change in Cash of Soligenix is 116,639.00 USD in 2025.

Net Change in Cash of Soligenix changed from -626,644.00 USD to 116,639.00 USD, representing a -118.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Soligenix since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Soligenix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Soligenix

All Key Metrics — Soligenix